Dose verification of eye plaque brachytherapy using spectroscopic dosimetry by Jarema, Talia et al.
University of Wollongong 
Research Online 
Faculty of Engineering and Information 
Sciences - Papers: Part A 
Faculty of Engineering and Information 
Sciences 
1-1-2016 
Dose verification of eye plaque brachytherapy using spectroscopic 
dosimetry 
Talia Jarema 
University Of Wollongong, Radiation Oncology Centres, tj395@uowmail.edu.au 
Dean L. Cutajar 
University of Wollongong, deanc@uow.edu.au 
Michael R. Weaver 
University of Wollongong, mweaver@uow.edu.au 
Marco Petasecca 
University of Wollongong, marcop@uow.edu.au 
Michael L. F Lerch 
University of Wollongong, mlerch@uow.edu.au 
See next page for additional authors 
Follow this and additional works at: https://ro.uow.edu.au/eispapers 
 Part of the Engineering Commons, and the Science and Technology Studies Commons 
Recommended Citation 
Jarema, Talia; Cutajar, Dean L.; Weaver, Michael R.; Petasecca, Marco; Lerch, Michael L. F; Kejda, Alannah; 
and Rosenfeld, Anatoly B., "Dose verification of eye plaque brachytherapy using spectroscopic dosimetry" 
(2016). Faculty of Engineering and Information Sciences - Papers: Part A. 6001. 
https://ro.uow.edu.au/eispapers/6001 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
Dose verification of eye plaque brachytherapy using spectroscopic dosimetry 
Abstract 
Eye plaque brachytherapy has been developed and refined for the last 80 years, demonstrating effective 
results in the treatment of ocular malignancies. Current dosimetry techniques for eye plaque 
brachytherapy (such as TLD- and film-based techniques) are time consuming and cannot be used prior to 
treatment in a sterile environment. The measurement of the expected dose distribution within the eye, 
prior to insertion within the clinical setting, would be advantageous, as any errors in source loading will 
lead to an erroneous dose distribution and inferior treatment outcomes. This study investigated the use 
of spectroscopic dosimetry techniques for real-time quality assurance of I-125 based eye plaques, 
immediately prior to insertion. A silicon detector based probe, operating in spectroscopy mode was 
constructed, containing a small (1 mm3) silicon detector, mounted within a ceramic holder, all 
encapsulated within a rubber sheath to prevent water infiltration of the electronics. Preliminary tests of 
the prototype demonstrated that the depth dose distribution through the central axis of an I-125 based 
eye plaque may be determined from AAPM Task Group 43 recommendations to a deviation of 6 % at 3 
mm depth, 7 % at 5 mm depth, 1 % at 10 mm depth and 13 % at 20 mm depth, with the deviations 
attributed to the construction of the probe. A new probe design aims to reduce these discrepancies, 
however the concept of spectroscopic dosimetry shows great promise for use in eye plaque quality 
assurance in the clinical setting. 
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Eye plaque brachytherapy has been developed and refined for the last 80 years, demonstrating 19 
effective results in the treatment of ocular malignancies. Current dosimetry techniques for eye plaque 20 
brachytherapy (such as TLD- and film- based techniques) are time consuming and cannot be used prior 21 
to treatment in a sterile environment. The measurement of the expected dose distribution within the eye, 22 
prior to insertion within the clinical setting, would be advantageous, as any errors in source loading will 23 
lead to an erroneous dose distribution and inferior treatment outcomes. This study investigated the use of 24 
spectroscopic dosimetry techniques for real-time quality assurance of I-125 based eye plaques, 25 
immediately prior to insertion. A silicon detector based probe, operating in spectroscopy mode was 26 
constructed, containing a small (1mm3) silicon detector, mounted within a ceramic holder, all 27 
encapsulated within a rubber sheath to prevent water infiltration of the electronics. Preliminary tests of 28 
the prototype demonstrated that the depth dose distribution through the central axis of an I-125 based 29 
eye plaque may be determined from AAPM Task Group 43 recommendations to a deviation of 6% at 30 
3mm depth, 7% at 5mm depth, 1% at 10mm depth and 13% at 20mm depth, with the deviations 31 
attributed to the construction of the probe. A new probe design aims to reduce these discrepancies, 32 
however the concept of spectroscopic dosimetry shows great promise for use in eye plaque quality 33 
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1. Purpose 43 
 44 
Ocular malignancies make up only a small fraction of incidences of malignancies and in 2011, there were 45 
predicted to be only 326 new cases of ocular malignancies in Australia [1, 2]. The use of eye plaque 46 
brachytherapy for the treatment of ocular malignancies has been researched and developed since the treatment’s 47 
first success using radon seeds in 1933 [3, 4]. Without eye plaque brachytherapy techniques, conditions such as 48 
uveal melanoma and squamous cell carcinoma would most likely be treated using enucleation. As other 49 
effective treatments such as proton therapy are not available in Australia, eye plaque brachytherapy has become 50 
the primary treatment method for many ocular malignancies as vision preservation is often a priority in 51 
treatment considerations [3]. 52 
 53 
In modern brachytherapy treatment centres, one of the most widely used isotopes for low dose-rate 54 
brachytherapy is Iodine 125 (I-125) [5]. The relatively low cost, short half-life (59.4 days), low emission energy 55 
and availability [6] have all led to frequent use of this radionuclide. In Australia, ROPES (Radiation and 56 
Oncology Physics and Engineering Services, Australia) eye plaques (Figure 1) are commonly used for eye 57 
plaque brachytherapy, and are designed to hold I-125 based seeds on an acrylic insert [5]. A stainless steel 58 





Figure 1. A rendering of the ROPESTM eye plaque, with stainless steel housing (left), acrylic insert (right) and I-125 64 
based seeds (lower) 65 
 66 
 67 
All treatments incorporating the use of radiation should be patient specific [7]. However, dosimetry for each 68 
individual treatment comprising physical measurements is challenging. Dose-rate measurements for eye plaque 69 
brachytherapy treatments have commonly been completed using thermoluminescent detectors (TLDs), film and 70 
Monte Carlo simulations [5]. The well-established protocol used for low dose-rate brachytherapy dose 71 
calculations is the AAPM Task Group 43 recommendations (TG-43) [6, 8], which uses analytical calculations 72 
constructed from measured and Monte Carlo generated point dose data.  73 
 74 
The procedure for using TLDs for pre-insertion verification in a clinical setting is designed to determine 75 
gross errors in plaque loading, including incorrect seed (activity) placement and potential rotational errors 76 
during loading [9]. However, as a dosimetric tool, TLDs do not have the spatial resolution required to gain 77 
important information about the effect of the treatment on small structures such as the optic disc and nerve, nor 78 
the intricate dose distribution within the eye [10].   79 
 80 
Radio-sensitive films may also be used for dosimetric verification. However the time needed for film 81 
processing renders it impractical for clinical pre-insertion dose verification. It is recommended that GafChromic 82 
EBT3 films be left at least 2 hours to achieve a stable reading [11, 12], hence resulting in the modality being 83 




Fast, pre-insertion dose verification of eye plaques would be beneficial to the treatment of ocular 86 
malignancies. One solution for the challenges presented by these common dosimetric techniques is the 87 
utilisation of spectroscopic dosimeters [13], which are able to produce results within a clinically appropriate 88 
timeframe, allowing gross dosimetric errors to be detected prior to plaque insertion. This is essential for 89 
verifying that the planned dose distribution will be delivered to the tumour. The Centre for Medical Radiation 90 
Physics (CMRP), University of Wollongong, has developed such a device [14], allowing fast point dose 91 
measurements for I-125 based brachytherapy treatments. This study was completed to determine the initial 92 
validity of spectroscopic dosimetry use in eye plaque brachytherapy.  93 
 94 
2. Theory 95 
I-125 based brachytherapy seeds such as the Oncura model 6711 and IsoAid Advantage IAI-125A have 96 
the unique advantage of emitting a pseudo mono-energetic spectrum. I-125 has dominant energy peaks at 27 97 
keV, 31 keV, 32 keV and 35.5 keV [13, 15]. Fluorescent peaks are observed at 22 keV and 25 keV caused by 98 
the silver rod within the brachytherapy seed [15]. Additionally, the dominant 27 keV peak is located centrally to 99 
the smaller surrounding peaks. At these low energies, the photoelectric effect is the major contributor to energy 100 
loss of photons in water. Although the Compton cross-section is significant, the energy loss due to Compton 101 
interactions is minimal. As a result, when traversing a water medium, the average energy of the spectrum does 102 
not significantly vary, with little formation of low energy tails on the photopeaks. Thus, with a consistent 103 
spectral shape, the number of events within the photopeaks of a measured spectrum per unit time will be 104 
proportional to the dose-rate at the point of measurement [16]. This is the basis of using spectroscopic dosimetry 105 
as an effective dosimetry tool for I-125 based treatments.  106 
 107 
While employing a detector and amplification system in spectroscopy mode, by setting a lower level 108 
threshold corresponding to events of energies lower than approximately 20 keV (below the photopeaks), the 109 
integral of counts within the spectrum above the threshold per unit time is used as the dose-rate measure. 110 
Spectroscopic dosimetry systems require an integral to dose conversion, which is obtained through calibration 111 
using sources of known activity at a fixed distance to the detector in a large water phantom. This may be 112 
achieved by placing the detector in a large water phantom along the transverse axis of an I-125 seed of known 113 
activity at a distance of 10 mm along and obtaining integral counts within the measured spectrum. In this case 114 
TG-43 recommendations will be used as the accepted protocol. 115 
 116 
 117 
3. Materials and Methods 118 
A spectroscopic dosimeter probe was developed as a prototype [14] featuring a 1mm3 silicon diode within a 119 
ceramic housing, mounted on a circuit board with preamplifier, covered in a polyethylene shield to provide a 120 
hermetic seal, as shown in Figure 2. The probe was connected to a data acquisition unit, containing a shaping 121 
amplifier, pulse height threshold gate, MCA/oscilloscope BNC output and onboard microprocessor for 122 
dosimetric calculations.  123 
 124 
 125 
Figure 2- Spectroscopic dosimeter developed at the CMRP, University of Wollongong. The tip is to the left, with the 126 




In this prototype detector, the sensitive volume of the spectroscopic dosimeter was found to be 129 
approximately 3 mm from the tip of the probe, as determined using a fluoroscopic x-ray, seen in Figure 3, 130 
limiting the minimum distance of measurement to a source to detector distance of 3mm.  131 
 132 
 133 
Figure 3- X-ray of the spectroscopic dosimeter showing the location of the sensitive volume relative to the tip 134 
Schematics of a clinical device for the quality assurance of an eye plaque prior to insertion, have been 135 
produced, as shown in Figure 4, with the prototype under development. This will allow for fast measurement 136 
and verification of the depth-dose profile along the central axis of treatment. The design features a water 137 
chamber with an internal holder for the eye plaque to separate the water from the plaque to retain a sterile 138 
condition. With the plaque facing upward in the water chamber, a probe of length approximately 50 mm, 139 
containing a silicon diode in the tip is lowered into the chamber, to the center of the plaque, against the inner 140 
surface. A computerised translational motion device is used to move the probe vertically away from the plaque 141 
in small increments, with the probe using spectroscopic dosimetry to provide a dose rate measure at each point. 142 
Measured point dose-rates are then correlated to planned dose-rates, with the entire measurement process 143 





Figure 4. A rendering of the spectroscopic eye plaque verification system 147 
 148 
3.1. Calibration and verification 149 
As all of the measurements were performed over a large time period, the results from all calibrations and 150 
measurements were normalised to the use of seeds of activity 0.4 mCi for consistency. Calibration of the system 151 
was verified using a single seed (IsoAid Advantage IAI-125), with an activity of 0.144 mCi, positioned 10 mm 152 
from the sensitive volume (detector) in liquid water. The system was programmed to count the number of pulses 153 
from the shaping amplifier which were above a threshold, representing the lowest energy to consider when 154 
tallying events in the detector (approximately 20 keV), with the threshold accurate to 6x10-4 keV. Once the 155 
lower level threshold was set, the dose calculation algorithm of the microprocessor was manually adjusted to 156 
give 0.20 cGy/hr dose-rate output on the data acquisition unit display. 157 
 158 
To ensure that the concept of spectroscopic dosimetry was valid across all depth measurements, an analysis 159 
of the spectrum was completed at each depth. The Full Width Half Maximum (FWHM) of the two dominant 160 
spectral peaks (22 and 27 keV), as seen in Figure 6 , were calculated with distances between the tip of the probe 161 
and the surface of the ROPES plaque ranging from 3 mm to 25 mm, as this range extends from close to the 162 
plaque surface to beyond the treatment range. For the concept of spectroscopic dosimetry to be valid, only the 163 
intensity of the peaks was expected to vary, with the FWHM and peak locations to have minimal change. 164 
 165 
3.2. Depth Dose Measurements 166 
Depth dose measurements through the central axis of the plaque were obtained using the prototype probe 167 
and were compared to analytically calculated doses (TG-43). The TG-43 calculations were performed over the 168 
range from 0.1 mm to 23 mm from the plaque inner surface, along the central axis, and were based on the 169 
location, orientation and activity of each seed within the plaque. 170 
 171 
To determine the depth dose curve of the ROPES eye plaque, water was used as the phantom material in a 172 
Perspex holder, designed specifically to ensure maximum setup reproducibility, as illustrated in Figure 5. 173 
Spectra were acquired at various depths, defined with a micrometer, and the dose-rate observed. This was 174 
completed in small increments. With the limitations of the current version of the probe, these started at 3 mm 175 
from the surface of the eye plaque and extended to 23 mm (approximately the diameter of the human eye) from 176 
the surface of the plaque. The depth was defined as the distance between the sensitive volume of the detector 177 
and the seed. The eye plaque was placed in a Perspex holder facing upwards, submerged in water. The 178 
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spectroscopic dosimeter was then attached to a micrometer to ensure accurate depth readings, as shown in 179 
Figure 5. 180 
 181 
All experimental setups and measurements were taken a minimum of 4 times to ensure accurate 182 
reproducibility of setup and movement of the detector, and were taken in both directions to rule out the 183 
introduction of hysteresis from the micrometer. This was limited by the orthogonality of the probe in relation to 184 










4. Results 195 
4.1. Calibration and verification 196 
The obtained spectrum at a depth of 1cm from the plaque surface on the central axis is shown in Figure 6. 197 
Four separate peaks are visible, located at approximately 22, 27, 31 and 36 keV, with the largest peaks being 22 198 
and 27 keV. The FWHM obtained for the 22 keV and 27 keV peaks as well as the relative location of the 199 
centroid (for a fixed calibration) are presented in Table 1 for varying depths in water. From the calibration depth 200 
of 10 mm, the peak centroid energy was within ±0.4 keV for both peaks, with the FWHM within ±0.3keV. The 201 
lack of spectral peak energy shift or change in FWHM demonstrates that the spectroscopic dosimeter should 202 
provide accurate dosimetric measurements within the required range of depths. The concept of spectroscopic 203 





Figure 6 I-125 based ROPES plaque spectrum, 10 mm in water from the plaque surface on the central 207 
axis 208 
 209 
Table 1 Analysis of the spectral peaks of I-125 at varying depths in water, distance measured from the sensitive 210 
volume of the probe 211 
 
22 keV Centroid 
(keV) 
22 keV FWHM 
(keV) 
27 keV Centroid 
(keV) 
27 keV FWHM 
(keV) 
5 mm 21.9 2.2 27.2 2.2 
10 mm 22 2.2 27.2 2.2 
15 mm 22.5 2.4 27.6 2.2 
20 mm 22.6 2.7 27.6 2.3 
25 mm 22.6 2.7 27.6 2.2 
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4.2. Depth Dose Measurements 212 
As shown in Figure 7, the experimental results gained from the spectroscopic dosimeter are accurate to 213 
within 6% standard uncertainty at 3 mm depth, 7% at 5 mm depth, 1% at 10 mm depth and 13% at 20 mm 214 
depth, when compared to TG-43 calculations.  215 
 216 
 217 
Figure 7 Depth dose data from 10, 0.4 mCi Oncura 6711 I-125 seeds loaded into a ROPES 15 mm eye plaque using 218 
the spectroscopic dosimeter.  Uncertainties shown are standard uncertainties from multiple measurements.219 
 220 
5. Discussion 221 
 222 
The depth-dose plot shows an over-response at close distances to the plaque and under-response at large 223 
distances. The main contributor to this discrepancy is the localisation of the sensitive volume within the probe 224 
tip. A mismatch of the sensitive volume location with respect to the probe tip will lead to an incorrect dose point 225 
location (at both calibration and measurement). The negative gradient in the discrepancy plot, whilst 226 
maintaining a high accuracy near the calibration depth (1cm) indicates that such a mismatch is present, with the 227 
detector being at a slightly smaller depth that 3mm from the probe tip. This emphasises the necessity that in the 228 
future detector design, the sensitive volume must be placed as close to the tip of the probe as possible, ensuring 229 
improved accuracy in the calibration and resultant measurements, as well as providing measurements closer to 230 
the plaque surface.  231 
 232 
Poder et al, 2013 [17], showed a decrease in dose at shallow depths from the plaque surface relative to TG-233 
43 dose calculations due to the presence of the stainless steel plaque encapsulation. In its current form, the eye 234 
plaque spectroscopic dosimeter does not have the accuracy to measure the dose rate at shallow depths from the 235 
plaque surface to verify this, however, the concept shows great promise to provide fast verification of dosimetry 236 
prior to plaque insertion. Future designs of the spectroscopic probe will have the detector housed within a 3D 237 
printed shell, with no presence of ceramic holders and with the detector location known to a more accurate level, 238 





5.1. Error Analysis 242 
 243 
Calibration was completed using a commercially available I-125 seed. This may have introduced 244 
additional errors into the measurements that were unaccounted for, as the seed strength was not traceable to a 245 
primary standards laboratory. However, as the purpose of this work was to determine if the detector had 246 
potential to be further developed as a real time dosimeter in eye plaque brachytherapy, the seed calibration was 247 
not of the utmost importance. Any variation in activity across the batch of seeds would have contributed to 248 
discrepancies in the plaque depth dose measurements. In future works, this will be of a higher priority.  249 
 250 
5.2. Limitations and further work 251 
 252 
One limitation encountered in this work is that presented by the TG-43 formalism. The formalism does not 253 
account for the backscatter introduced by the steel backing plate of the ROPES eye plaque. In future studies, 254 
modelling the eye plaque and seeds using Monte Carlo may give a better standard to which the results may be 255 
compared. However, this particular work was limited to exploring the results against the current “gold standard” 256 
of brachytherapy, TG-43, regardless of the flaws it presents. 257 
 258 
Future work will address the limitation of alignment that would have been easily introduced into this work 259 
through the production of an automated measurement system. Great care was taken to ensure that the probe was 260 
moving perpendicularly to the center of the plaque at all times. However, there was no way to verify that the 261 
central axis of movement aligned orthogonally with the centre of the plaque. Small angulations and geometric 262 
uncertainties, such as central axis alignment, do have the potential to produce an incorrect assessment of dose-263 
rate, despite the reproducibility of the setup. Results presented in this study were a combination of data points 264 
collected over multiple studies, minimising the influence of many geometric errors. 265 
 266 
Looking beyond the scope of this project, it will be possible to apply this approach to develop an estimation 267 
of the radiation dose to the organs at risk in the immediate vicinity of the orbit. This would be of particular 268 
advantage in terms of the dose received by the region of the brain closest to the orbit and could be achieved 269 
through a slight modification of the experimental setup. Most importantly, it would require expanding the 270 
phantom dimensions and utilising a 3D motion controlling system. 271 
 272 
 273 
6. Conclusion 274 
Eye plaque brachytherapy treatments require rigorous planning and dosimetry considerations due to the 275 
delicate nature of the procedure. A fast quality assurance system for the verification of treatment dosimetry 276 
immediately prior to insertion is desired, however, prohibited by limitations on current dosimetry techniques. 277 
For use in the dosimetry of eye plaque brachytherapy, spectroscopic dosimetry has the potential to provide 278 
results that are accurate, informative and instantaneous. The results from the spectroscopic dosimeter, being 279 
easily reproduced and giving real time data are evidence toward the implementation of such detectors in centres 280 
using eye plaque brachytherapy, as a common treatment modality. As the spectroscopic dosimetry system 281 
displays the measured dose-rates in real time, the dosimetric technique has the potential to be used clinically for 282 
eye plaque brachytherapy. Based on the presented prototype, version II of the eye plaque spectroscopic 283 
dosimeter as well as the computer controlled eye plaque verification system, is in production, with clinical 284 
implementation to proceed in the near future. 285 
 286 
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